Business Wire

VALBIOTIS

Share
Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros

Regulatory News:

Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, today announces the large successful capital increase through a private placement open to certain categories of beneficiaries launched the previous day and achieved using an accelerated bookbuilding process. Given the very high demand from French and international investors, Valbiotis decided to set the amount of the capital increase at 15 million euros, compared to approximately 12 million euros initially forecast.

Sébastien PELTIER, CEO of Valbiotis stated: "I am extremely grateful to all the new investors who participated in this capital increase, as well as all our historic shareholders who continue to support our company in its mission and its development. This capital increase is key, as it will enable us to accelerate our development program for the prevention of high blood pressure with the aim of marketing by 2023, up to three years ahead of our initial schedule. It will also contribute to the achievement of our preclinical programs across our entire portfolio and to the strengthening of our supply chain in view of, among other things, the future commercialization of TOTUM•63 in prediabetes by Nestlé Health Science. Thanks to these new resources, that secure the execution of our roadmap in the long term, we have everything we need to succeed!”

Allocation of funds to the development strategy of Valbiotis

The net proceeds of the capital increase of approximately 14.2 M€ are primarily intended to finance the acceleration of the development of TOTUM•854 (prevention of arterial hypertension) with the launch of three clinical trials at the end of this year including a Phase II/III clinical trial prior to a health claim application. In partnership with a major healthcare player, TOTUM•854 could then be marketed at the end of this study, up to 3 years ahead of the initial schedule.

This acceleration comes in the wake of the positive preclinical results obtained with this active substance, presented at the annual ESH – ISH congress (press release of April 12, 2021 ) and available on the Company website (www.valbiotis.com/en ). These results obtained in vivo on predictive models of human hypertension have shown that TOTUM•854 effectively prevents arterial hypertension, considered as the number one chronic disease worldwide with over 124 million people with moderately high blood pressure in the United States and the 5 main European countries (Germany, Spain, France, Italy, and the United Kingdom) alone. This represents an addressable market for Valbiotis worth an estimated 1.15 billion euros (source: AEC Partners, 2020).

The capital increase will also help to extend Valbiotis' funding horizon and enable the Company to reach the next steps in value creation of its various products:

  • funding of preclinical research on the other products in the portfolio;
  • reinforcement of staff, mainly clinical and supply chain teams, to prepare the upcoming marketing of TOTUM•63 in prediabetes by Nestlé Health Science;
  • financing the Company’s overall costs until first semester 2024.

Main characteristics of the capital increase

Valbiotis has issued 1,930,000 new shares at a unit price of 7.80 euros, share premium included, which corresponds to a nominal value of 0.10 euros and a share premium of 7.70 euros, for a gross amount of 15,054,000 euros. This represents 25% of the share capital of Valbiotis before the capital increase and an overall dilution of 20%.

The capital increase was executed with the removal of shareholders’ preferential subscription rights through a private placement using an accelerated bookbuilding process with both French and international qualified investors belonging to the category of persons referred to in the 13th resolution of the Shareholders’ Annual General Meeting held on May 28, 2020.

The Board set the subscription price at 7.80 euros per new share. This price, fixed under the conditions provided for in the above-mentioned 13th resolution, represents a 5.1% discount compared to the closing price of the Company shares on April 14, 2021.

Incidence of the capital increase on the capital distribution

This transaction will result in an increase of the share capital of Valbiotis from 777,626.20 euros to 970,626.20 euros divided by 9,706,262 shares with a nominal value of 0.10 euros each, and is broken down as follows:

Before offering

 

After offering

Shareholders

Number of

shares

% of

capital

 

Number of

shares

% of

capital

 

Stake of Board members (1)

1,006,051

12.9%

1,006,051

10.4%

Sébastien PELTIER

(via Djanka Investissement and as an individual)

647,100

8.3%

647,100

6.7%

Jocelyn PINEAU

(via Financière ELOUJON and as an individual)

349,751

4.5%

349,751

3.6%

Pascal SIRVENT

9,200

0.1%

9,200

0.1%

 

Stake of Supervisory Board members (1)

13,400

0.2%

13,400

0.1%

Laurent LEVY

10,400

0.1%

10,400

0.1%

Sébastien BESSY

3,000

0.0%

3,000

0.0%

 

Liquidity contract (2)

10,679

0.1%

10,679

0.1%

 

Public

6,746,132

86.8%

8,676,132

89.4%

 

TOTAL

7,776,262

100%

9,706,262

100%

(1)

The other members of the Board and Supervisory Board do not hold any shares. It is recalled that all the members of the Board and the Supervisory Board together hold 867,124 share warrants and share warrants for entrepreneurs out of a total of 1,140,046 share warrants and share warrants for entrepreneurs issued.

(2)

Data from the session on March 31, 2020.

The allocation of voting rights is as follows:

Before offering

After offering

Shareholders

Number of

shares

% of

capital

Number of

shares

% of

capital

 

Stake of Board members (1)

1,863,551

21.5%

1,863,551

17.6%

Sébastien PELTIER

(via Djanka Investissement and as an individual)

1,252,100

14.4%

1,252,100

11.8%

Jocelyn PINEAU

(via Financière ELOUJON and as an individual)

602,251

6.9%

602,251

5.7%

Pascal SIRVENT

9,200

0.1%

9,200

0.1%

 

Stake of Supervisory Board members (1)

13,400

0.2%

13,400

0.1%

Laurent LEVY

10,400

0.1%

10,400

0.1%

Sébastien BESSY

3,000

0.03%

3,000

0.03%

 

Liquidity contract (2)

-

0.0%

-

0.0%

 

Public

6,808,460

78.4%

8,738,460

82.3%

 

TOTAL

8,685,411

100%

10,615,411

100%

(1)

The other members of the Board and Supervisory Board do not hold any shares. It is recalled that all the members of the Board and the Supervisory Board together hold 867,124 share warrants and share warrants for entrepreneurs out of a total of 1,140,046 share warrants and share warrants for entrepreneurs issued.

(2)

Data from the session on March 31, 2020.

Impact on the situation of the shareholder

Based on the post-transaction share capital, the stake of a shareholder holding 1% of the capital of the Company before the capital increase and not having subscribed to the latter now holds 0.80%.

Shareholder stake

Non-diluted

basis

Diluted basis (1)

1%

0.88%

0.80%

0.72%

(1) Taking into account the subscription of 1,930,000 new shares likely to be created to date.

The impact on the equity per share is as follows:

Equity (1) per share

on December 31, 2020

Non-diluted

basis

Diluted basis (1)

0.92 €

0,81 €

0.74 €

0.66 €

(1) Established according to the IFRS and before charging expenses against the issue premium, based on audited accounts, closed and not approved at December 31, 2020.
(2) Taking into account the subscription of 1,930,000 new shares likely to be created to date

Admission to trading of new shares

The new shares will bear dividend rights and will be admitted to trading on the Euronext Growth Paris market under the same ISIN code: FR0013254851 – ALVAL. They will be subject to all statutory provisions and will be ranked with the existing shares upon completion of the capital increase. The settlement of the new shares and their admission to trading on the Euronext Growth Paris market is scheduled within 3 working days.

The information presented in this press release is so following the placement of shares through an accelerated bookbuilding process, now closed, but remains subject to the correct execution of the settlement transactions.

Pursuant to the provisions of Article 211-3 of the General Regulation of the Autorité des marchés financiers and Article 1(4) of Regulation (EU) 2017/1129, the Offer has not resulted in or will not result in the preparation of a prospectus submitted to the AMF for approval.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150

Warning

This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties mentioned in this press release. This document is available on the Company's website (www.valbiotis.com ).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

As a reminder, pursuant to the provisions of Article 211-3 of the General Regulations of the Autorité des marchés financiers and Article 1, 4 of Regulation (EU) 2017/1129, the offer of the Company's shares in the context of the capital increase carried out for the benefit of a category of persons meeting specific characteristics, in particular qualified French and international investors, will not give rise to a prospectus subject to the visa of the Autorité des marchés financiers .

Detailed information about Valbiotis, including its business, results and risk factors, has been presented in the annual financial report for the financial year ending December 31, 2020, in the half-year financial report for the period ending June 30, 2020 and in the registration agreement approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). These documents, as well as other regulated information and press releases, can be consulted on the Company's website (www.valbiotis.com ).

This press release is for information purposes only. This press release does not constitute and shall not be deemed to constitute an offer to the public, an offer to subscribe, an offer to sell or a solicitation of interest to the public in connection with any transaction by way of public offering of securities in any jurisdiction.

Securities may be offered or sold in the United States only pursuant to registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from such registration requirement. The securities of the Company that are the subject of this press release have not been and will not be registered under the Securities Act, and the Company does not intend to conduct a public offering of the securities that are the subject of this press release in the United States.

The release, publication or distribution of this press release in certain countries may violate applicable laws. The information contained in this press release does not constitute an offer of securities in France, the United States, Canada, Australia, Japan or any other country. This press release may not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan. This document does not constitute an offer to sell or a public offering of Valbiotis shares in the United States or in any other country.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Year-old European startup Maisa named alongside Google and Amazon in elite list of leading AI agent vendors in top global US research reports by Gartner3.7.2025 01:01:00 CEST | Press release

- First time a Spanish startup has made the list, thanks to its industry-first hallucination resistant ‘digital workers’ - AI startup is one of two European AI agent vendors in Gartner’s Hype Cycle report for Artificial Intelligence and Hype Cycle for the Future of Work lists Maisa, a rising star of enterprise AI, has been named by leading global research and advisory firm Gartner in its list of leading vendors for developing reliable AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702640749/en/ Maisa founders David Villalón and Manuel Romero Inclusion in Gartner’s 2025 Hype Cycle for AI and Hype Cycle for the Future of Work marks the first time a Spanish startup has been mentioned in these influential reports. The company, which is barely a year old and made its first raise of $5m+ from leading US investors last year, now finds itself named alongside global giants Amazon Web Services, Google, Salesforce and Lan

Hoffmann Green Announces a Historic Increase in Production Over the First Half of 2025, Already Outperforming the Annual Volumes Realized in 20242.7.2025 19:05:00 CEST | Press release

Record activity levels: +151% increase in production volumes in H1 2025 vs. H1 2024More than 130 construction sites supplied with more than 60,000 m³ of 0% clinker concrete delivered by 10,000 truck mixers across the countryAcceleration driven by a strengthened partnership network and the successful diversification of targeted marketsSolid outlook for the second half of 2025, in line with the strategic roadmap Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, today announces a strong acceleration of production over the first half of 2025, validating the relevance of its industrial and commercial business model. Production volumes reached 19,640 tonnes over the first half of 2025, compared with 7,833 tonnes in the first half of 2024, representing a 2.5-fold increase. This very strong leve

Institutional Real Estate, Inc. Announces Acquisition of U.K.-based Lyndon Publishing 2 Limited2.7.2025 18:44:00 CEST | Press release

Institutional Real Estate, Inc. (“IREI”) has completed its acquisition of the assets of London-based Lyndon Publishing 2 Ltd (“Lyndon Publishing”), which include The Property ChronicleandThe Green Chronicle.The former Lyndon Publishing 2 will now operate as a division of IREI. The Property Chronicle reaches a global audience of real estate investment professionals, researchers, and academics. Its sister publication, The Green Chronicle, is edited to address the interests and concerns of emerging young talent in these real estate professions. Both publications are produced as weekly news briefings filled with original content and contributed feature articles from industry thought and opinion leaders. In addition, The Property Chronicle is also published as a quarterly, illustrated full-color magazine available in both digital and print formats, while The Green Chronicleis published exclusively in digital format. Together, the two publications reach approximately 50,000 professionals acr

Sinopec Wins Technological Innovation Award at 2nd Sino-European Corporate ESG Best Practice Conference2.7.2025 18:21:00 CEST | Press release

China Petroleum & Chemical Corporation ("Sinopec", HKG: 0386) has won the "Best Scientific and Technological Innovation Practice" award at the 2nd Sino-European Corporate ESG Best Practice Conference (the "Conference") on June 26 in Stuttgart. Sinopec’s case submission of Breakthrough in Depth, Climb to New Heights — Empowering the Energy and Chemical Industry with Technological Innovation stood out among numerous entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702387465/en/ Wang Tao, Sinopec representative, delivered a speech at the conference. The Conference reviews and awards the best ESG application cases in six areas of environmental protection, social responsibility, corporate management, scientific and technological innovation, education, and training to further enhance mutual understanding between Chinese and European businesses, facilitate bilateral economic and trade exchanges, and showcase China’s open,

Xsolla Releases Their Q2 2025 The State of Play Report: Mobile Gaming Is Projected to Hit $126B in 2025 Amid Global App Boom With In-Depth Analysis of Trends, Genres, and Monetization Strategies2.7.2025 18:00:00 CEST | Press release

Key Topics Include In-App Purchase Trends, Genre Performance, Player Demographics, D2C Strategy Adoption, and Hybrid Monetization Models Xsolla, a leading global video game commerce company, proudly announces the release of the Q2 2025 Edition of “The Xsolla Report: The State of Play.” This detailed report provides crucial insights, trends, and opportunities shaping the gaming landscape, empowering industry professionals to adapt and thrive in today’s rapidly changing market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702208715/en/ Graphic: Xsolla In 2024, global mobile app usage soared to an astonishing 4.2 trillion hours, an all-time high that powered a massive $150 billion consumer spending across mobile platforms. Mobile gaming is leading this charge, which accounted for more than half of that total. Despite a 6% dip in overall game downloads, falling to 49.6 billion, in-app purchase (IAP) revenue surged, indicati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye